EUVIMEDEUVIMED entdecken
Open Access

Quantitative Measurement of HER2 Expression in Non–Small Cell Lung Cancer With a High-Sensitivity Assay

Matthew Liu, Ioannis Vathiotis, Charles J Robbins, Nay Nwe Nyein Chan, Myrto Moutafi, Sneha Burela, Vasiliki Xirou, Kurt A Schalper, Roy S Herbst, Konstantinos Syrigos, David L Rimm

Modern Pathology · 2024-09 · 37 (9) · 100556

DOI: 10.1016/j.modpat.2024.100556 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2024-09. Verfasst von Matthew Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Yale University School of Medicine, New Haven, Connecticut. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Biomarkers, Tumor. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS, Breast Cancer Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recently, low human epidermal growth factor receptor 2 (HER2) protein expression has been proposed as a predictive biomarker for response to the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) in metastatic breast cancer. HER2 expression in non-small cell lung cancer (NSCLC) patients has never been carefully measured, and little is known about the frequency of cases with unamplified but detectable levels of the protein. Although some HER2-targeted therapies have been studied in NSCLC patients, they have been restricted to those with genomic ERBB2 gene alterations, which only represent relatively rare cases of NSCLC. Still, emerging investigations of T-DXd in NSCLC have shown promise in patients with unamplified HER2. Taken together, we hypothesize that there may be many cases of NSCLC with levels of HER2 protein expression comparable with levels seen in breast cancer that benefit from T-DXd. Here, we used a previously validated, analytic, quantitative immunofluorescence (QIF) assay that is more sensitive than legacy clinical HER2 immunohistochemistry assays. We measured HER2 protein levels in NSCLC cases to determine the proportion of cases with detectable HER2 expression. Using cell line calibration microarrays alongside our QIF method enabled us to convert HER2 signal into units of attomoles per mm2. We found that over 63% of the 741 analyzed NSCLC cases exhibited HER2 expression above the limit of detection, with more than 17% of them exceeding the lower limit of quantification. Although the threshold for response to T-DXd in breast cancer is still unknown, many cases of NSCLC have expression in a range comparable to breast cancer cases with immunohistochemistry scores of 1+ or 2+. Our assay could potentially select NSCLC cases with a detectable target (ie, HER2) that might benefit from HER2 antibody-drug conjugates, irrespective of ERBB2 genomic alterations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsErb-b2 Receptor Tyrosine KinasesBiomarkers, TumorHumansFemaleAgedMiddle AgedMaleTrastuzumabAntineoplastic Agents, ImmunologicalImmunoconjugatesCamptothecin

Stichwörter der Autor:innen

ERBB2growth factorimmunohistochemistrynon–small cell lung cancerquantitative immunofluorescence

Substanzen

Erb-b2 Receptor Tyrosine KinasesBiomarkers, TumorTrastuzumabAntineoplastic Agents, ImmunologicalImmunoconjugatesCamptothecinERBB2 protein, humantrastuzumab deruxtecan

Autor:innen und Institutionen

  • Department of Pathology, Yale University School of Medicine, New Haven, Connecticut.
  • Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Department of Medicine, Yale University School of Medicine, New Haven, Connecticut.
  • Department of Pathology, Yale University School of Medicine, New Haven, Connecticut; Department of Medicine, Yale University School of Medicine, New Haven, Connecticut. Electronic address: david.rimm@yale.edu.

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS
  • Breast Cancer Research Foundation
  • NIH

Zitieren

APA

Liu, M., Vathiotis, I., Robbins, C. J., Chan, N. N. N., Moutafi, M., Burela, S., Xirou, V., Schalper, K. A., Herbst, R. S., Syrigos, K., & Rimm, D. L. (2024). Quantitative Measurement of HER2 Expression in Non–Small Cell Lung Cancer With a High-Sensitivity Assay. Modern Pathology, 37(9), 100556. https://doi.org/10.1016/j.modpat.2024.100556

Vancouver

Liu M, Vathiotis I, Robbins CJ, Chan NNN, Moutafi M, Burela S, et al. Quantitative Measurement of HER2 Expression in Non–Small Cell Lung Cancer With a High-Sensitivity Assay. Modern Pathology. 2024;37(9):100556. doi:10.1016/j.modpat.2024.100556

BibTeX
@article{Liu2024,
  author = {Liu, Matthew and Vathiotis, Ioannis and Robbins, Charles J and Chan, Nay Nwe Nyein and Moutafi, Myrto and Burela, Sneha and Xirou, Vasiliki and Schalper, Kurt A and Herbst, Roy S and Syrigos, Konstantinos and Rimm, David L},
  title = {Quantitative Measurement of HER2 Expression in Non–Small Cell Lung Cancer With a High-Sensitivity Assay},
  journal = {Modern Pathology},
  year = {2024},
  volume = {37},
  number = {9},
  pages = {100556},
  doi = {10.1016/j.modpat.2024.100556}
}
Kostenlos starten →